Abstract 366P
Background
Microbiome has been proposed as a promising prognostic biomarker in various types of cancer. Although recent microbiome studies have linked the bacterial microbiome in the oral cavity and nasopharynx to the prognosis of nasopharyngeal carcinoma (NPC), the clinical significance of oral mycobiome, another key player of the oral microbiome, in NPC survival remain unknown.
Methods
We enrolled 476 untreated incident NPC patients from Wuzhou, southern China during March 2010 and December 2013, with follow-up through December 2018. We collected saliva samples at the time of diagnosis and characterized the oral mycobiome using fungal internal transcribed spacer (ITS)-2 sequencing. We analyzed the relationship between oral mycobiome and the overall survival using Cox regression adjusting for multiple confounders.
Results
Overall, the average follow-up of the NPC patients [mean (SD) age, 48.5 (10.7) years; 72% male) was 5.26 years. Patients with lower oral fungal alpha diversity (measured by observed features) had an inferior 5-year overall survival rate (lower group vs. higher group = 54.9% vs. 69.6%, P for log-rank test = 0.007). We found that lower alpha diversity was associated with an increased mortality [lower vs. higher: observed features (fully adjusted hazard ratio [HR] = 1.56, 95% confidence interval [CI] = 1.08-2.25); Simpson diversity (1.50, 1.04-2.15); Shannon diversity (1.79, 1.25-2.56)]. The associations were attenuated when further adjusted for cancer stage at diagnosis, and the significant associations were found only among localized-tumor-stage patients.
Conclusions
Oral mycobiome is a potential prognostic biomarker for patients with NPC and might provide potential guidance for treatment decision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The original field work was supported by a grant from the National Cancer Institute at the US National Institutes of Health (grant number: R01 CA115873). This work was supported by the Swedish Research Council (grant numbers: 2015-02625, 2015-06268, 2017-05814, 2019-01429), and the High-level Talents Research Start-up Project of Fujian Medical University (grant numbers: XRCZX2017035 and XRCZX2020034), the National Natural Science Foundation of China (grant number: U22A20322). Yufeng Chen was also partly supported by a scholarship from China Scholarship Council (grant number: 201600160071).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract